JPS57130914A - Prolongation of activity retention - Google Patents

Prolongation of activity retention

Info

Publication number
JPS57130914A
JPS57130914A JP56015254A JP1525481A JPS57130914A JP S57130914 A JPS57130914 A JP S57130914A JP 56015254 A JP56015254 A JP 56015254A JP 1525481 A JP1525481 A JP 1525481A JP S57130914 A JPS57130914 A JP S57130914A
Authority
JP
Japan
Prior art keywords
active substance
cyclodextrin polymer
vessel
membrane
permeable membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP56015254A
Other languages
English (en)
Inventor
Kazuaki Harada
Satoshi Morimoto
Keishiro Tsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Advanced Industrial Science and Technology AIST
Original Assignee
Agency of Industrial Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency of Industrial Science and Technology filed Critical Agency of Industrial Science and Technology
Priority to JP56015254A priority Critical patent/JPS57130914A/ja
Priority to US06/343,214 priority patent/US4432802A/en
Publication of JPS57130914A publication Critical patent/JPS57130914A/ja
Pending legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989Microcapsule with solid core [includes liposome]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)
JP56015254A 1981-02-04 1981-02-04 Prolongation of activity retention Pending JPS57130914A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP56015254A JPS57130914A (en) 1981-02-04 1981-02-04 Prolongation of activity retention
US06/343,214 US4432802A (en) 1981-02-04 1982-01-27 Inclusion compound-containing composite

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56015254A JPS57130914A (en) 1981-02-04 1981-02-04 Prolongation of activity retention

Publications (1)

Publication Number Publication Date
JPS57130914A true JPS57130914A (en) 1982-08-13

Family

ID=11883713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56015254A Pending JPS57130914A (en) 1981-02-04 1981-02-04 Prolongation of activity retention

Country Status (2)

Country Link
US (1) US4432802A (ja)
JP (1) JPS57130914A (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152765A (ja) * 1984-12-27 1986-07-11 Nippon Ekishiyou Kk シクロデキストリン類で包接された化合物を含有した合成樹脂製品及びその製造方法
JPS6215A (ja) * 1985-02-26 1987-01-06 Fujisawa Pharmaceut Co Ltd 2−ニトロオキシメチル−6−クロロピリジンまたはそのβ−シクロデキストリン包接化合物含有持続性製剤
JPS61291984A (ja) * 1985-06-18 1986-12-22 Ichiro Shibauchi 防錆材の製造方法
JPS6327502A (ja) * 1986-07-22 1988-02-05 Agency Of Ind Science & Technol シクロデキストリン−シリカ複合体及びその製造方法
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
ZA885069B (en) * 1987-07-24 1989-03-29 Fujisawa Pharmaceutical Co Sustained-release percutaneous preparations
JPH0269540A (ja) * 1988-09-05 1990-03-08 Chisso Corp 結晶性ポリオレフイン組成物
US5075432A (en) * 1989-08-11 1991-12-24 Edward Vanzo Spherical cyclodextrin polymer beads
DE69127805T2 (de) * 1990-10-01 1998-03-12 Toppan Printing Co Ltd Cyclodextrin-polymer sowie daraus hergestellter cyclodextrin-film
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
DE19734244A1 (de) * 1997-08-07 1999-02-11 Wacker Chemie Gmbh Zusammensetzung umfassend einen Komplex von Cyclodextrin mit Isothiazolinon in einer wasserlöslichen Hülle und dessen Verwendung
US6653524B2 (en) 1999-12-23 2003-11-25 Kimberly-Clark Worldwide, Inc. Nonwoven materials with time release additives
KR100785913B1 (ko) * 2006-11-29 2007-12-17 한국과학기술연구원 경화된 β-사이클로덱스트린 중합체 분말과 그의 제조방법
CA2692211C (en) 2009-12-14 2011-09-13 Cellresin Technologies, Llc Maturation or ripening inhibitor release from polymer, fiber, film, sheet or packaging
US10182567B2 (en) 2011-03-27 2019-01-22 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
RU2559463C2 (ru) 2011-03-27 2015-08-10 СЕЛЛРЕЗИН ТЕКНОЛОДЖИЗ, ЭлЭлСи Композиция на основе циклодекстрина, содержащий ее упаковочный материал и способ его плучения
US9320288B2 (en) 2012-11-30 2016-04-26 Cellresin Technologies, Llc Controlled release compositions and methods of using
US9421793B2 (en) 2014-06-26 2016-08-23 Cellresin Technologies, Llc Electrostatic printing of cyclodextrin compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) * 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
GB1538075A (en) * 1975-03-24 1979-01-10 Champion Paper Co Ltd Formation of microcapsules by interfacial cross-linking and microcapsules produced thereby
JPS55130909A (en) * 1979-03-31 1980-10-11 Agency Of Ind Science & Technol Granular material containing active substance and having inactive surface-protecting layer, and its preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives

Also Published As

Publication number Publication date
US4432802A (en) 1984-02-21

Similar Documents

Publication Publication Date Title
JPS57130914A (en) Prolongation of activity retention
GB1336495A (en) Method of manufacture of devices for emitting vapours of active volatile agents
EP0147464A4 (en) CHEMICALLY ACTIVE AQUEOUS SOLUTION AND SOLID SUBSTANCE IRON (II) -ION CONTAINING.
KR970703175A (ko) 용액의 제조 및 저장 방법(Method of Manufacturing and Storing Solutions)
AU589678B2 (en) Gelatine capsules and process for their manufacture
GB1422854A (en) Hollow filament encapsulating therein enzyme microorganism or both and preparation thereof
ES8402720A1 (es) Procedimiento para la obtencion de una composicion a base de estireno para revestir alimentos y medicamentos.
HUT47570A (en) Insecticides containing as active substance 3-substituated-1-/chlor-tiasole-5-il-methil/-2-nitroamin-1,3-diaza-cycloalkans and process for production of the active substances
ES8202349A1 (es) Un procedimiento para la preparacion de una composicion po- limerica hidroxilada sintetica.
GB1456930A (en) Foams and sponge sheet for cigar manufacture
EP0161681A3 (en) Gel plate and process for preparing same
IE893810L (en) Stabilizing packaged iodophor and minimizing leaching of¹iodine through packaging
NL188527C (nl) Werkwijze ter bereiding van een een dimethoxychinazolinederivaat bevattend geneesmiddel, gevormd geneesmiddel met bloeddrukverlagende werking en werkwijze ter bereiding van de werkzame stof.
IE871040L (en) Butter aroma composition
GB1377618A (en) Composition and device for impelementing the delivery storage and use of microorganisms
KR900701665A (ko) 정수 시스템
MY104654A (en) Osmotic absorbents.
IE780784L (en) Tea bags
JPS52156932A (en) Remedy for diabetes
GB1480615A (en) Catamenial device
GB1441320A (en) Method of removing bacteria and water droplets from a gas stream
Garg et al. The synthesis of the 1-N-(L-aspart-4-oyl) glucosylamine linkage. New synthesis of 1-N-(L-aspart-1-and 4-oyl)-4-O-beta-D-galactopyranosyl-beta-D-glucopyranosylamines
Levin The content of components of the fibrinolytic system in the platelets of donor and fibrinolytic blood
JPS54151184A (en) Washed cell body mixture
Lindahl-Kiessling et al. High oxygen pressure inhibits DNA synthesis in mitogen-activated lymphocytes